Oncology (all articles)
ASTRO Guideline | Radiation therapy for IDH-mutant grade 2 and grade 3 diffuse glioma.
29 Jul, 2022 | 12:33h | UTC
M-A | Lung cancer occurrence after an episode of tuberculosis.
29 Jul, 2022 | 12:28h | UTC
Guideline | Pediatric differentiated thyroid carcinoma.
29 Jul, 2022 | 12:31h | UTC
Cohort Study | Assessment of second primary cancer risk among men receiving primary radiotherapy vs. surgery for the treatment of prostate cancer.
29 Jul, 2022 | 12:23h | UTC
Commentary on Twitter
In this cohort study of patients with localized prostate cancer, radiotherapy was associated with a small increase in the risk of developing a second primary cancer. https://t.co/YsrNo3FKwM
— JAMA Network Open (@JAMANetworkOpen) July 28, 2022
Long-term results of a RCT | Active maintenance Olaparib vs. Placebo for germline BRCA-mutated metastatic pancreatic cancer.
29 Jul, 2022 | 12:18h | UTCOverall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary on Twitter
OS data from the POLO trial of maintenance olaparib vs placebo for pts with BRCA-mutant PDAC reveal no significant benefit (median 19.0 vs 19.2 months) although the curves separated at 24 months & 3-yr OS was 33.9% vs 17.8%; other outcomes favour olaparib: https://t.co/JZ28MsGV0B
— NatureRevClinOncol (@NatRevClinOncol) July 20, 2022
NICE Guideline Update | Melanoma: assessment and management.
28 Jul, 2022 | 13:21h | UTCMelanoma: assessment and management – National Institute for Health and Care Excellence
Cohort Study | Androgen-deprivation therapy and risk of death from cardio-vascular disease in prostate cancer patients.
28 Jul, 2022 | 13:13h | UTCNews Release: Hormone therapy for prostate cancer increases the risk of dying from cardiovascular disease – Taylor & Francis
RCT | Efficacy and safety of topical hypericin photodynamic therapy for early-stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides).
28 Jul, 2022 | 13:09h | UTCEfficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical Trial – JAMA Dermatology (free for a limited period)
Commentary on Twitter
The findings of this randomized clinical trial indicate that synthetic hypericin photodynamic therapy is effective in early-stage patch and plaque mycosis fungoides−cutaneous T-cell lymphoma and has a favorable safety profile. https://t.co/hHfDESptQF
— JAMA Dermatology (@JAMADerm) July 21, 2022
M-A | Breast cancer recurrence after immediate and delayed postmastectomy breast reconstruction.
28 Jul, 2022 | 13:05h | UTC
M-A | Toxicity profiles of systemic therapies for advanced hepatocellular carcinoma.
26 Jul, 2022 | 12:34h | UTC
Commentary on Twitter
This meta-analysis of 30 high-quality RCTs in patients with advanced hepatocellular carcinoma found that immune checkpoint inhibitors were associated with similar liver toxicity but lower serious adverse events compared to tyrosine kinase inhibitors. https://t.co/i0gJg0bqdX
— JAMA Network Open (@JAMANetworkOpen) July 18, 2022
Systematic Review | Taxane monotherapy regimens for treating recurrent epithelial ovarian cancer.
25 Jul, 2022 | 12:47h | UTC
RCT | Follow-up schedule for patients with sentinel node negative cutaneous melanoma.
25 Jul, 2022 | 12:43h | UTCFollow-up Schedule for Patients with Sentinel Node Negative Cutaneous Melanoma: an International Phase III Randomised Clinical Trial – Annals of Surgery (link to abstract – $ for full-text)
5-year outcomes of a RCT | Encorafenib plus Binimetinib vs. Vemurafenib or Encorafenib in patients with BRAF V600–mutant melanoma.
25 Jul, 2022 | 12:41h | UTC
RCT | Effectiveness of intensive vs. minimalist follow-up regimen on survival in patients with endometrial cancer.
25 Jul, 2022 | 12:42h | UTCEffectiveness of Intensive Versus Minimalist Follow-Up Regimen on Survival in Patients With Endometrial Cancer (TOTEM Study): A Randomized, Pragmatic, Parallel Group, Multicenter Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)
Perspective | Achieving diagnostic excellence for cancer: symptom detection as a partner to screening.
22 Jul, 2022 | 11:44h | UTCAchieving Diagnostic Excellence for Cancer: Symptom Detection as a Partner to Screening – JAMA (free for a limited period)
Review | Anesthesia after neoadjuvant chemotherapy, immunotherapy or radiotherapy.
22 Jul, 2022 | 11:21h | UTCAnaesthesia after neoadjuvant chemotherapy, immunotherapy or radiotherapy – BJA Education
Practical recommendations to combine small-molecule inhibitors and direct oral anticoagulants in patients with nonsmall cell lung cancer.
22 Jul, 2022 | 11:07h | UTC
RCT | Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer.
21 Jul, 2022 | 13:25h | UTCPembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Among patients with triple-negative breast cancer and high expression of PD-L1, pembrolizumab plus chemotherapy resulted in longer overall survival than chemotherapy alone. https://t.co/5urffgHdFb pic.twitter.com/2GlmJuYZJz
— NEJM (@NEJM) July 20, 2022
RCT | Laparoscopic vs. open distal gastrectomy for locally advanced gastric cancer.
21 Jul, 2022 | 13:00h | UTCSee also: Visual Abstract
Commentary: Laparoscopy Noninferior to Open Surgery in Locally Advanced Gastric Cancer – MedPage Today (free registration required)
Related:
Laparoscopic vs Open Distal Gastrectomy for Locally Advanced Gastric Cancer: Five-Year Outcomes From the CLASS-01 Randomized Clinical Trial – JAMA Surgery (link to abstract – $ for full-text)
Morbidity and Mortality of Laparoscopic vs Open Total Gastrectomy for Clinical Stage I Gastric Cancer: The CLASS02 Multicenter Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)
Survival outcomes after laparoscopy-assisted distal gastrectomy versus open distal gastrectomy with nodal dissection for clinical stage IA or IB gastric cancer (JCOG0912): a multicentre, non-inferiority, phase 3 randomised controlled trial – The Lancet Gastroenterology & Hepatology (link to abstract – $ for full-text)
Effect of Laparoscopic Distal Gastrectomy vs Open Distal Gastrectomy on Long-term Survival Among Patients With Stage I Gastric Cancer: The KLASS-01 Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)
Retrospective Cohort Study | Major adverse cardiovascular events in patients with renal cell carcinoma treated with targeted therapies.
21 Jul, 2022 | 12:54h | UTC
Single-arm study | Intensive multimodality therapy for extraocular retinoblastoma.
21 Jul, 2022 | 12:25h | UTCIntensive Multimodality Therapy for Extraocular Retinoblastoma: A Children’s Oncology Group Trial (ARET0321) – Journal of Clinical Oncology (link to abstract – $ for full-text)
RCT | Oral Paclitaxel plus Encequidar vs. intravenous Paclitaxel in patients with metastatic breast cancer.
21 Jul, 2022 | 12:24h | UTC
Commentary on Twitter
Oral Paclitaxel is an alternative treatment option to every 3-week paclitaxel with more neutropenic serious infections and less incidence and severity of neuropathy for patients with advanced or mBChttps://t.co/wNrLfs2myN pic.twitter.com/l3aWGhEdwU
— K Pavithran (@drkpavithran) July 21, 2022
M-A | Risk and benefit for umbrella trials in oncology.
21 Jul, 2022 | 12:27h | UTC
Guidelines on the diagnosis and treatment of prostate cancer.
20 Jul, 2022 | 12:11h | UTCThe Swedish national guidelines on prostate cancer – Scandinavian Journal of Urology
Part 2: Recurrent, metastatic and castration resistant disease
Updates on enhanced recovery after surgery for radical cystectomy.
20 Jul, 2022 | 12:03h | UTCUpdates on enhanced recovery after surgery for radical cystectomy – Therapeutic Advances in Urology
Related:
Complete List of Enhanced Recovery After Surgery (ERAS) Society Guidelines